stoxline Quote Chart Rank Option Currency Glossary
  
Apollomics, Inc. (APLM)
0.21  0.012 (5.97%)    07-16 10:48
Open: 0.193
High: 0.21
Volume: 65,437
  
Pre. Close: 0.1985
Low: 0.193
Market Cap: 23(M)
Technical analysis
2024-07-16 10:17:09 AM
Short term     
Mid term     
Targets 6-month :  0.25 1-year :  0.28
Resists First :  0.22 Second :  0.24
Pivot price 0.19
Supports First :  0.18 Second :  0.15
MAs MA(5) :  0.19 MA(20) :  0.2
MA(100) :  0.43 MA(250) :  1.57
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  25.3 D(3) :  22.5
RSI RSI(14): 43.2
52-week High :  6.19 Low :  0.18
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ APLM ] has closed below upper band by 27.2%. Bollinger Bands are 80.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.21 - 0.21 0.21 - 0.21
Low: 0.19 - 0.19 0.19 - 0.19
Close: 0.2 - 0.2 0.2 - 0.2
Company Description

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Headline News

Fri, 12 Jul 2024
Apollomics, Inc. (NASDAQ:APLM) Sees Significant Increase in Short Interest - Defense World

Wed, 29 May 2024
Apollomics Announces Presentation at the 2024 BIO International Convention - Yahoo Finance

Wed, 08 May 2024
Apollomics Announces Private Placement Financing and Addition to Board of Directors - GlobeNewswire

Thu, 25 Apr 2024
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene - Yahoo Finance

Thu, 28 Mar 2024
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results - GlobeNewswire

Thu, 28 Mar 2024
Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 110 (M)
Held by Insiders 3.987e+007 (%)
Held by Institutions 48 (%)
Shares Short 82 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.345e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -8 %
Return on Assets (ttm) 368.4 %
Return on Equity (ttm) -50.8 %
Qtrly Rev. Growth 821000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -43 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.54
Stock Dividends
Dividend 0
Forward Dividend 80170
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android